Endurance Wealth Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Endurance Wealth Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-124	Closed	-$22K	–	662
2021 Q2	$22K	Hold	124	–	–	﹤0.01%	443
2021 Q1	$19K	Hold	124	–	–	﹤0.01%	460
2020 Q4	$19K	Hold	124	–	–	﹤0.01%	428
2020 Q3	$14K	Hold	124	–	–	﹤0.01%	440
2020 Q2	$14K	Hold	124	–	–	﹤0.01%	442
2020 Q1	$11K	Hold	124	–	–	﹤0.01%	424
2019 Q4	$13K	Hold	124	–	–	﹤0.01%	406
2019 Q3	$12K	Buy	+124	New	+$14K	﹤0.01%	409

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Endurance Wealth Management's ALXN Position: Q3 2021 in Review

Endurance Wealth Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 124 shares — an estimated $22K sold.

Endurance Wealth Management first reported a position in ALXN in Q3 2019 and held it in 8 quarters. The position peaked at $22K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Endurance Wealth Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Endurance Wealth Management sold 124 Alexion Pharmaceuticals shares in Q3 2021, an estimated $22K.
Endurance Wealth Management first reported a position in Alexion Pharmaceuticals in Q3 2019 and held it in 8 quarters.
Endurance Wealth Management's Alexion Pharmaceuticals position peaked at $22K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Endurance Wealth Management's 13F filing for Q3 2021, filed 28 Oct 2021.